The company said revenue for Q1 of December 31, 2023 was $4,706 million, up 2.6% from $4,586 million a year earlier. It said GAAP diluted earnings per share were $0.96 and adjusted diluted EPS was $2.68.

1. 01

   The company said revenue for Q1 of December 31, 2023 was $4,706 million, up 2.6% from $4,586 million a year earlier. It said GAAP diluted earnings per share were $0.96 and adjusted diluted EPS was $2.68.

2. 02

   The company said BD Medical revenue for Q1 rose 3.5% to $2,230 million, and BD Interventional revenue rose 5.2% to $1,188 million. BD Life Sciences revenue fell 1.0% to $1,288 million.

3. 03

   The company said net cash provided by continuing operating activities for Q1 was $855 million, compared with $399 million a year earlier. It said it used $500 million for share repurchases and $275 million for dividend payments over the same period.

4. 04

   The company raised its adjusted diluted EPS guidance for fiscal 2024 to $12.82 to $13.06 from $12.70 to $13.00. It said it now expects revenue of about $20.2 billion to $20.4 billion, compared with $20.1 billion to $20.3 billion previously.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.